Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents.
This article reviews and critiques the use of intravenous tPA for acute stroke. Guidelines on which patients should receive tPA are proposed with a particular emphasis placed on onset time. The current status of other potential stroke therapies are also reviewed, including neuroprotective trials and agents designed to limit reperfusion injury.
Clark
W M
WM
Department of Neurology, Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201, USA. clarkw@ohsu.edu
Lutsep
H L
HL
D000721:Ancrod / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000098:blood supply; D020520:Brain Infarction / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015427:Reperfusion Injury / Q000175:diagnosis / Q000517:prevention & control*; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents; D013300:Streptokinase; D000721:Ancrod; D010959:Tissue Plasminogen Activator